South Korean in-vitro diagnostic medical device startup AllMade announced on April 8 that it has secured seed funding from the Bigbang Hightech Bio Fund, managed by Bigbang Ventures.

With this investment, AllMade will accelerate the development of its next-generation in-vitro diagnostic platform, which leverages the luminescent signals of quantum dots. Quantum dots are ultra-fine semiconductor particles, typically just a few to several dozen nanometers in size, that emit different colors depending on their size. AllMade is developing a diagnostic technology that combines these quantum dots with biomaterials, along with a high-sensitivity sensing system capable of precisely analyzing the signals.

Founded in 2023, AllMade was selected in 2024 for the Ministry of SMEs and Startups’ Startup Growth Technology Development (R&D) Leap Project and is currently focused on advancing its core technologies, with plans to launch its first product in 2025.

Taehoon Koo, CEO of Bigbang Ventures, explained the investment decision, saying, “AllMade’s quantum dot-based, high-sensitivity diagnostic technology shows strong potential in the global animal in-vitro diagnostic market, especially in the livestock sector.”

Taek-kyu Oh, CEO of AllMade, commented, “This investment gives us the momentum to target the niche between rapid and precision diagnostics, and to accelerate our entry into the market.”